Opinion

Video

Tazemetostat as Third-line and Beyond Therapy for FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Related Videos
Peter Forsyth, MD
Minoo Battiwalla, MD, MS
Richard Kim, MD, Moffitt Cancer Center
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Tiago Biachi, MD, PhD
Related Content
Dana-Farber Cancer Institute Faculty Among Highly Cited Researchers | Image Credit: © Cornflakesei - stock.adobe.com
November 21st 2024

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Tanios S. Bekaii-Saab, MD
November 19th 2024

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Tanios S. Bekaii-Saab, MD
November 17th 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation